Apeloa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Apeloa Pharmaceutical Co Ltd cash flow-to-debt ratio. Apeloa Pharmaceutical Co Ltd (000739) has a Cash Flow-to-Debt Ratio of 0.07x as of December 2025, meaning its operating cash flow of CN¥446.18 Million could theoretically repay 0% of its total liabilities (CN¥5.97 Billion) in one year. Check Apeloa Pharmaceutical Co Ltd (000739) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Apeloa Pharmaceutical Co Ltd (1998–2025)
Cash flow-to-debt ratio of Apeloa Pharmaceutical Co Ltd from 1998 to 2025. Historical debt coverage capacity for Apeloa Pharmaceutical Co Ltd across 28 annual periods. Check Apeloa Pharmaceutical Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Apeloa Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (1998–2025)
Apeloa Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 1998 to 2025. Year-by-year debt coverage analysis for Apeloa Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 000739 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.21x | CN¥1.23 Billion | CN¥5.97 Billion | ▲ +1.9% |
| 2024 | 0.20x | CN¥1.21 Billion | CN¥5.98 Billion | ▲ +28.1% |
| 2023 | 0.16x | CN¥1.03 Billion | CN¥6.54 Billion | ▼ -22.6% |
| 2022 | 0.20x | CN¥1.33 Billion | CN¥6.50 Billion | ▲ +32.8% |
| 2021 | 0.15x | CN¥611.75 Million | CN¥3.98 Billion | ▼ -55.0% |
| 2020 | 0.34x | CN¥1.06 Billion | CN¥3.10 Billion | ▼ -30.9% |
| 2019 | 0.49x | CN¥1.36 Billion | CN¥2.75 Billion | ▲ +42.7% |
| 2018 | 0.35x | CN¥832.69 Million | CN¥2.41 Billion | ▲ +335.6% |
| 2017 | 0.08x | CN¥209.80 Million | CN¥2.64 Billion | ▲ +32.2% |
| 2016 | 0.06x | CN¥180.42 Million | CN¥3.00 Billion | ▼ -59.4% |
| 2015 | 0.15x | CN¥441.16 Million | CN¥2.98 Billion | ▼ -48.1% |
| 2014 | 0.29x | CN¥786.64 Million | CN¥2.76 Billion | ▲ +320.3% |
| 2013 | 0.07x | CN¥190.45 Million | CN¥2.80 Billion | ▼ -44.6% |
| 2012 | 0.12x | CN¥335.90 Million | CN¥2.74 Billion | ▼ -27.5% |
| 2011 | 0.17x | CN¥404.62 Million | CN¥2.40 Billion | ▲ +44.6% |
| 2010 | 0.12x | CN¥121.05 Million | CN¥1.04 Billion | ▼ -46.4% |
| 2009 | 0.22x | CN¥208.30 Million | CN¥954.91 Million | ▲ +124.4% |
| 2008 | 0.10x | CN¥94.57 Million | CN¥973.00 Million | ▼ -51.8% |
| 2007 | 0.20x | CN¥174.20 Million | CN¥864.02 Million | ▲ +4.8% |
| 2006 | 0.19x | CN¥159.43 Million | CN¥828.68 Million | ▲ +61.3% |
| 2005 | 0.12x | CN¥87.40 Million | CN¥732.94 Million | ▲ +86.4% |
| 2004 | 0.06x | CN¥47.54 Million | CN¥743.40 Million | ▼ -67.6% |
| 2003 | 0.20x | CN¥105.36 Million | CN¥534.24 Million | ▲ +2672.0% |
| 2002 | 0.01x | CN¥2.81 Million | CN¥395.59 Million | ▲ +509.1% |
| 2001 | 0.00x | CN¥-569.79K | CN¥327.67 Million | ▼ -104.4% |
| 2000 | 0.04x | CN¥7.08 Million | CN¥177.79 Million | ▲ +141.2% |
| 1999 | -0.10x | CN¥-20.52 Million | CN¥212.40 Million | ▼ -172.9% |
| 1998 | 0.13x | CN¥30.10 Million | CN¥227.17 Million | — |